Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Telotristat Ethyl in Severe Hepatic Impairment
NCT03423446Phase 1Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Nov 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of telotristat ethyl in Carcinoid Syndrome (CS) (2 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoints: Maximum observed concentration of telotristat ethyl at 4 days, Time of maximum observed concentration of telotristat ethyl at 4 days and 1 more. Started Nov 2017; status: completed.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT03423446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03423446.